12 completed, 8 recruiting, 4 withdrawn, 3 terminated. 33 Phase 1, 14 Phase 2.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NALIRIFOX+Adebrelimab, PULSAR - Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 55 | 2026-04-01 | 2026-05-19 |
| Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy Oral Immunotherapy, Allergenic food avoidance - Food Allergy in Children | Phase 1 / Phase 2 | Recruiting | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 68 | 2026-02-18 | 2026-02-27 |
| Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol Vitamin B6-restricted diet + immunotherapy - Solid Tumor Cancer | Phase 1 | Active not recruiting | West China Hospital | 20 | 2025-12-01 | 2026-09-02 |
| Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. Radiotherapy combined with immunotherapy - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | China-Japan Friendship Hospital | 38 | 2025-08-01 | 2025-02-27 |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors MOMA-341, Irinotecan, Immunotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | MOMA Therapeutics | 132 | 2025-07-16 | 2026-07-23 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer Biopsy, Biospecimen Collection, Bone Scan - Breast Carcinoma, Colorectal Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2025-05-27 | 2026-11-03 |
| NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC NAD supplement, Radiotherapy, Immunotherapy - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Sichuan University | 20 | 2025-05-01 | 2025-05-12 |
| Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma Dinutuximab beta, chemotherapy treatment called GPOH, chemotherapy treatment called rapid COJEC - Neuroblastoma | Phase 1 | Recruiting | Princess Maxima Center for Pediatric Oncology | 38 | 2025-01-28 | 2025-07-08 |
| A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus Lysogenic HSV virus., Tislelizumab, Afatinib - HNSCC, Lysogenic HSV Virus | Phase 1 | Withdrawn | West China Hospital | 2024-12-15 | 2026-10-16 | |
| Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer hypofractionated radiotherapy with immunotherapy - Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Anhui Provincial Hospital | 45 | 2024-07-01 | 2024-09-19 |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-03-28 | 2024-05-01 | |
| Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) Novel combination of chemotherapy and immunotherapy - Cholangiocarcinoma | Phase 1 / Phase 2 | Terminated | University of Alabama at Birmingham | 1 | 2023-01-30 | 2024-11-05 |
| Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy - Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Shanghai Chest Hospital | 50 | 2023-01-10 | 2023-12-18 |
| Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Pleural Mesothelial Neoplasm | Phase 1 | Completed | Mayo Clinic | 20 | 2021-07-12 | 2026-07-08 |
| Boiled Peanut Oral Immunotherapy Boiled Peanut Powder - Peanut Hypersensitivity | Phase 1 | Completed | Alton Melton | 8 | 2019-11-05 | 2024-09-19 |
| Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer Chemotherapy, Immunotherapy, IMRT - Rectal Cancer, Radiotherapy | Phase 1 / Phase 2 | Suspended | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2019-11-01 | 2024-01-03 |
| Thermal Ablation Followed by Immunotherapy for HCC Thermal ablation, Toripalimab - Hepatocellular Carcinoma Non-resectable | Phase 1 / Phase 2 | Unknown | Xiangya Hospital of Central South University | 145 | 2019-06-15 | 2022-09-29 |
| Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Nivolumab, GM.CD40L Vaccine - Lung Cancer, Adenocarcinoma of the Lung | Phase 1 / Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2018-07-01 | 2019-09-09 |
Showing 20 of 33. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Neoplasm Metastasis (3) · Brain Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Glioblastoma (2) · Melanoma (2) · Neoplasms (2) · Neuroblastoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Central Nervous System Diseases (1)
H. Lee Moffitt Cancer Center and Research Institute (5) · West China Hospital (4) · St. Jude Children's Research Hospital (2) · Aduro Biotech, Inc. (1) · Alton Melton (1) · Anhui Provincial Hospital (1) · BinYong Liang (1) · China-Japan Friendship Hospital (1) · City of Hope Medical Center (1) · DNAtrix, Inc. (1) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1) · Immunsystem AB (1) · Jonsson Comprehensive Cancer Center (1) · MOMA Therapeutics (1) · Mayo Clinic (1)
United States (16) · China (10) · Australia (1) · France (1) · India (1) · Netherlands (1) · Spain (1) · Sweden (1)
Xingchen Peng (2) · Annika Hollsing, MD, PhD (1) · Frederick Lang, MD (1) · Gregory A Hale, MD (1) · Guangying Zhu, M.D. (1) · Holger Lode, MD, PhD (1) · Jaclyn Bjelac, MD (1) · Jeffrey Y Wong (1) · Jessica Frakes, M.D. (1) · Jhanelle Gray, M.D. (1) · Jianxin Xue, doctoral (1) · Karen Fink, MD, PhD (1) · Liangrong Shi, M.D. (1) · Moh'd Khushman, MD (1)
PMID 20842054, PMID 21561347, PMID 21699798, PMID 22658128, PMID 24131140, PMID 24145345, PMID 31263030, PMID 32043778, PMID 32671834, PMID 32827353, PMID 33794306, PMID 34439389, PMID 34726575, PMID 36450385, PMID 37280366, PMID 37459862, PMID 37708904, PMID 37820884, PMID 38572751, PMID 38589494, PMID 39008192, PMID 39089313, PMID 39448025, PMID 39575028, PMID 39687891, PMID 40204149
2023 (1), P30CA033572 (1), R01CA283603 (1)